TSXV:BTI.H - Post by User
Comment by
prophetoffactzon Dec 19, 2022 7:53pm
132 Views
Post# 35181076
RE: MTX110
RE: MTX110 Looks like some clinical data within about one month against the ultra-rare pediatric brain cancer DIPG. There has already been one phase I trial with 7 patients with remarkable though non-statistically significant results for survival(26 months vs. 10 months). If the results are confirmed in this second study I wonder how strong the read-through is to the glioblastoma trial recently initiated which uses the same drug. Glioblastoma is a $5 billion market so even a 10% chance of success could be meaningful in terms of value. Average life expectancy for glioblastoma is only 12-18 months so the timeline to outcome once enrolled isn't that long. "In addition, the company expects to report data in the next couple of months from the second Phase I study assessing MTX110 in DIPG, conducted by Columbia University." Edison Group November 15 Midatech Pharma - Patient recruitment begins in rGBM study | Edison (edisongroup.com) ------ "As a reminder, Midatech had earlier (in October 2020) presented interim data from its other UCSF conducted Phase I study, which not only met its primary endpoint in terms of safety but also demonstrated exceptionally positive early efficacy signals, including median overall survival of 26.06 months (CI 11.3–26.06 months) versus 10 months following standard of care radiation therapy." Midatech Pharma - Interim DIPG data to be presented at ISPNO | Edison (edisongroup.com)